June 2nd 2021
By Tony Hagen
Real-world clinical data compiled for patients with autoimmune disorders were presented at EULAR 2021.
May 24th 2021
An antibody conjugate, Ujvira combines the cancer cell growth–fighting properties of trastuzumab with the cytotoxic capability of emtansine.
May 17th 2021
Investigators evaluated both biosimilar vs originator savings and savings from earlier use of a lower-cost adalimumab biosimilar (Amgevita).
May 14th 2021
By Deana Ferreri, PhD
A Canada study of the filgrastim biosimilar Grastofil demonstrated equivalence to Neupogen in candidates for autologous stem cell transplantation (ASCT), an extrapolated use.
May 13th 2021
A second class of biosimilars that are considered "interchangeable" could set biosimilars back in terms of acceptance, according to Albert Kim, MBA.
May 12th 2021
With COVID-19 on the retreat, Coherus BioSciences sees the advantage wearing off for Amgen's pegfilgrastim injector kit.
When it comes to biologics, there is a constant push and pull over patent rights. Some believe this is part of a healthy market-driven economy. Others are skeptical.
May 11th 2021
After being sued for allegedly stealing adalimumab process information, Alvotech fires back.
April 22nd 2021
Allen Lising, managing director of Xcenda’s FormularyDecisions, explains how stakeholders are using pre-approval information to make business decisions.
April 9th 2021
The latest e-book from The Center for Biosimilars® offers insightful content on patient education, biosimilar development, and regulatory issues.
